Debate: Is allotransplant relevant today in myeloma? - No

Debate: Is allotransplant relevant today in myeloma? - YesПодробнее

Debate: Is Transplant a Necessity or a Choice for Myeloma Patients? - NoПодробнее

Should MRD Guide Myeloma Treatment? A Debate. | Rahul Banerjee, MD and Sridevi Rajeeve, MD |IMS 2024Подробнее

Debate: To maintain or not to maintain in myeloma? - No, but if you must, use a proteasome inhibitorПодробнее

Allotransplant: Is there a Role in Myeloma?Подробнее

Debate: Is Transplant a Necessity or a Choice for Myeloma Patients? - YesПодробнее

Debate: Should alkylators be used upfront in transplant-ineligible myeloma patients? - NoПодробнее

Debate: Myeloma maintenance post-transplant - None or LimitedПодробнее

Timing for Myeloma CAR-T Therapy: A Debate | Rahul Banerjee, MD and Sridevi Rajeeve, MD | IMS 2024Подробнее

Myeloma Debate: Is MRD Ready for Prime Time? - NoПодробнее

Debate: Ideal Treatment fro Smoldering MyelomaПодробнее

Debate: Myeloma maintenance post-transplant - IndefiniteПодробнее

Myeloma Debate: Is MRD Ready for Prime Time? - YesПодробнее

Optimal use of transplantation in myeloma: Early, late, non-ablative?Подробнее

Multiple Myeloma Debate 2014: Recent advances in multiple myelomaПодробнее

Debate: High risk myeloma: Should it be treated differently? - NoПодробнее

Debate: Optimal Induction Therapy for Newly Diagnosed Transplant Eligible Myeloma - TripletsПодробнее

Debate: Use of MRD measurements in myeloma - Not yet ready for prime time in standard careПодробнее

Debate: Upfront transplant remains a standard of care - NoПодробнее